"Prekurzory karcinomu prsu" . . "26" . "Petr\u00E1kov\u00E1, Katar\u00EDna" . "It has become apparent that estrogen receptor (ER) - positive and - negative breast lesions are completely distinct diseases. Precursors of low-grade breast cancer are low-grade premalignant lesions, usually ER and progesterone receptor (PR) positive and HER2 negative. On the other hand, precursors of high-grade breast cancer are high-grade premalignant lesions, usually ER and PR negative and HER2 positive. Lobular neoplasia (LN) and ductal carcinoma in situ (DCIS) are important from the clinical point of view. LN increases the risk of bilateral breast cancer. This is why the recommendation for the treatment of LN is very different \u2013 from just following-up up to bilateral mastectomy. The complete surgical excision of the lesion with negative margins is the usual treatment of DCIS. Several big randomized clinical trials showed the benefit of adjuvant radiotherapy (RT). Some of them suppose that there is a group of patients who do not need adjuvant treatment. The benefit of adjuvant tamoxifen is clear only for patients with ER positive disease. The UK/ ANZ study showed the benefit of tamoxifen only in patients without RT."@en . "Prekurzory karcinomu prsu"@cs . "RIV/00209805:_____/13:#0000453" . "Nenutil, Rudolf" . . "Klinick\u00E1 onkologie" . . . "CZ - \u010Cesk\u00E1 republika" . . . "Prekurzory karcinomu prsu s n\u00EDzk\u00FDm stupn\u011Bm malignity jsou zpravidla premalign\u00ED l\u00E9ze tak\u00E9 s n\u00EDzk\u00FDm stupn\u011Bm malignity, v\u017Edy s pozitivitou estrogenov\u00FDch (ER) a progesteronov\u00FDch receptor\u016F (PR) a negativitou HER2. Naopak, prekurzory karcinom\u016F s vysok\u00FDm stupn\u011Bm malignity jsou zpravidla premalign\u00ED l\u00E9ze tak\u00E9 s vysok\u00FDm stupn\u011Bm malignity a p\u0159ev\u00E1\u017En\u011B ER a PR negativn\u00ED, s p\u0159\u00EDpadnou pozitivitou HER2. V \u010Dl\u00E1nku jsou pops\u00E1ny jednotliv\u00E9 l\u00E9ze a jejich vztah ke karcinomu. Doporu\u010Den\u00ED pro l\u00E9\u010Dbu lobul\u00E1rn\u00EDch neoplazi\u00ED (LN) jsou m\u00E9n\u011B jednozna\u010Dn\u00E1 ne\u017E doporu\u010Den\u00ED pro l\u00E9\u010Dbu dukt\u00E1ln\u00EDho karcinomu in situ (DCIS). LN zvy\u0161uj\u00ED riziko karcinomu prsu bilater\u00E1ln\u011B na rozd\u00EDl od DCIS. Doporu\u010Den\u00ED pro n\u00E1slednou l\u00E9\u010Dbu se proto pohybuj\u00ED v rozmez\u00ED od pouh\u00E9ho sledov\u00E1n\u00ED a\u017E po bilater\u00E1ln\u00ED mastektomii. Z\u00E1kladn\u00ED l\u00E9\u010Dbou DCIS je l\u00E9\u010Dba chirurgick\u00E1, a to kompletn\u00ED excize lo\u017Eiska s negativn\u00EDmi okraji. N\u011Bkolik velk\u00FDch randomizovan\u00FDch klinick\u00FDch studi\u00ED prok\u00E1zalo p\u0159\u00EDnos adjuvantn\u00ED radioterapie (RT). N\u011Bkter\u00E9 pr\u00E1ce v\u0161ak p\u0159edpokl\u00E1daj\u00ED, \u017Ee existuje skupina pacientek, kter\u00E9 by mohly b\u00FDt pouze sledov\u00E1ny. P\u0159\u00EDnos l\u00E9\u010Dby tamoxifenem byl pozorov\u00E1n pouze u pacientek s pozitivitou ER a PR, a to pouze v p\u0159\u00EDpad\u011B, \u017Ee bylo zva\u017Eov\u00E1no i sn\u00ED\u017Een\u00ED rizika kontralater\u00E1ln\u00EDho DCIS a invazivn\u00EDho karcinomu. Ve studii UK/ ANZ byl tamoxifen p\u0159\u00EDnosn\u00FD jen u pacientek bez adjuvantn\u00ED RT. Proto je pot\u0159eba jeho indikaci zva\u017Eovat individu\u00E1ln\u011B." . "Precursors of breast cancer"@en . "3"^^ . . . "Supplementum" . . "http://www.linkos.cz/files/klinicka-onkologie/182/4353.pdf" . "3"^^ . "Prekurzory karcinomu prsu s n\u00EDzk\u00FDm stupn\u011Bm malignity jsou zpravidla premalign\u00ED l\u00E9ze tak\u00E9 s n\u00EDzk\u00FDm stupn\u011Bm malignity, v\u017Edy s pozitivitou estrogenov\u00FDch (ER) a progesteronov\u00FDch receptor\u016F (PR) a negativitou HER2. Naopak, prekurzory karcinom\u016F s vysok\u00FDm stupn\u011Bm malignity jsou zpravidla premalign\u00ED l\u00E9ze tak\u00E9 s vysok\u00FDm stupn\u011Bm malignity a p\u0159ev\u00E1\u017En\u011B ER a PR negativn\u00ED, s p\u0159\u00EDpadnou pozitivitou HER2. V \u010Dl\u00E1nku jsou pops\u00E1ny jednotliv\u00E9 l\u00E9ze a jejich vztah ke karcinomu. Doporu\u010Den\u00ED pro l\u00E9\u010Dbu lobul\u00E1rn\u00EDch neoplazi\u00ED (LN) jsou m\u00E9n\u011B jednozna\u010Dn\u00E1 ne\u017E doporu\u010Den\u00ED pro l\u00E9\u010Dbu dukt\u00E1ln\u00EDho karcinomu in situ (DCIS). LN zvy\u0161uj\u00ED riziko karcinomu prsu bilater\u00E1ln\u011B na rozd\u00EDl od DCIS. Doporu\u010Den\u00ED pro n\u00E1slednou l\u00E9\u010Dbu se proto pohybuj\u00ED v rozmez\u00ED od pouh\u00E9ho sledov\u00E1n\u00ED a\u017E po bilater\u00E1ln\u00ED mastektomii. Z\u00E1kladn\u00ED l\u00E9\u010Dbou DCIS je l\u00E9\u010Dba chirurgick\u00E1, a to kompletn\u00ED excize lo\u017Eiska s negativn\u00EDmi okraji. N\u011Bkolik velk\u00FDch randomizovan\u00FDch klinick\u00FDch studi\u00ED prok\u00E1zalo p\u0159\u00EDnos adjuvantn\u00ED radioterapie (RT). N\u011Bkter\u00E9 pr\u00E1ce v\u0161ak p\u0159edpokl\u00E1daj\u00ED, \u017Ee existuje skupina pacientek, kter\u00E9 by mohly b\u00FDt pouze sledov\u00E1ny. P\u0159\u00EDnos l\u00E9\u010Dby tamoxifenem byl pozorov\u00E1n pouze u pacientek s pozitivitou ER a PR, a to pouze v p\u0159\u00EDpad\u011B, \u017Ee bylo zva\u017Eov\u00E1no i sn\u00ED\u017Een\u00ED rizika kontralater\u00E1ln\u00EDho DCIS a invazivn\u00EDho karcinomu. Ve studii UK/ ANZ byl tamoxifen p\u0159\u00EDnosn\u00FD jen u pacientek bez adjuvantn\u00ED RT. Proto je pot\u0159eba jeho indikaci zva\u017Eovat individu\u00E1ln\u011B."@cs . "RIV/00209805:_____/13:#0000453!RIV14-MSM-00209805" . . . . "Precursors of breast cancer"@en . . "[2B8A84137BAD]" . . "Prekurzory karcinomu prsu" . "0862-495X" . "98888" . . . . "Pal\u00E1cov\u00E1, Mark\u00E9ta" . . "Prekurzory karcinomu prsu"@cs . "P(ED2.1.00/03.0101)" . "6"^^ . "premalignant lesion; lobular carcinoma in situ; lobular neoplasia; ductal carcinoma in situ"@en . .